Type to search

News Resources Smart Labs Uncategorized

DotLab Announces Three Granted Patents for Its Non-invasive Test for Endometriosis, DotEndo™

Share
DotLab Announces Three Granted Patents for Its Non-invasive Test for Endometriosis, DotEndo™ | Pharmtech Focus

DotLab, a medical diagnostics company, announced that the United States Patent and Trademark Office has granted three key patents for its technology focused on the diagnosis, assessment, and characterization of endometriosis. Via its clinical studies, DotLab has pioneered medical tests enabled by single-stranded, non-coding RNAs called microRNAs in circulating body fluids such as blood and saliva. The inventions embodied in the portfolio of granted patents – U.S. Patent No. 10,982,282, U.S. Patent No. 11,220,713, and U.S. Patent No. 11,315,660 B2 – also include the company’s proprietary machine learning algorithms to detect, predict, diagnose, and monitor the presence or absence of the disease.

The training set for the DotEndo™ machine learning algorithm was developed via DotLab’s EMPOWER clinical study, a prospective, observational, multi-center study run at endometriosis centers of excellence across the United States. EMPOWER is the most robust clinical study of its type ever performed, making it an excellent foundation for the commercial test.

“DotLab tackled a holy grail in women’s health – endometriosis – which is notorious for its complex biology and the sheer scale of the unmet medical need,” said DotLab’s CEO Heather Bowerman. “We’re proud to share the news of these inventions and intellectual property achievements, which are ultimately a much-needed win for millions of patients.”

DotLab’s validation study was published in the American Journal of Obstetrics & Gynecology, the official publication of the American Gynecological & Obstetrical Society, Association of Professors of Gynecology and Obstetrics, Infectious Diseases Society for Obstetrics and Gynecology, Society for Maternal-Fetal Medicine, and Society of Gynecologic Surgeons.

Tags:

People in this post:

Companies in this post:

Next Up